REPAIR-MDS – a ground breaking clinical trial for low/intermediate risk MDS
3 Aug. 2023October 2024 - Update
Repair-MDS is now closed to recruitment. Once there are results and data available, which is expected to be in early-mid 2025, we will post this here.
On behalf of the trial managers, the clinical team, and ourselves on the PPIE (Patient and Public Involvement and Education) front, can we take this opportunity to say a big THANK YOU to those members who signed up and actively participated.
A new diagnosis of low/intermediate risk MDS can be shocking – hearing you have cancer, that it's life limiting and that there are very few treatments available, may well be distressing. Often, the only real option for patients is to return home and 'watch and wait' until the next appointment, usually three months away. The REPAIR-MDS trial offered a chance to get involved in one of two new experimental treatment options.
What is the REPAIR-MDS trial?
REPAIR-MDS is a ground-breaking clinical trial that aims to improve the symptoms and overall quality of life for patients with low/intermediate risk Myelodysplastic Syndromes. Patients were put randomly into one of two treatment groups below. Both groups used drugs which are already used safely for other diseases (Repurposed drugs).
Treatment Group 1 VBaP - Sodium Valproate (V), Bezafibrate (Ba), Medroxyprogesterone (P)
Treatment Group 2 : Danazol.
The study is trying to find out if these ‘repurposed’ drugs can be used to treat MDS patients and to improve their blood counts, reduce their need for transfusions, improve their quality of life, and prolong their survival.
Where are the trial sites?
The trial is taking place throughout the UK, is coordinated by the University of Warwick’s Clinical Trials Unit and was open in around 30 hospitals.
Follow the link to the REPAIR-MDS website for a regularly updated list of REPAIR-MDS trial sites
What's the trial duration?
September 2020 - June 2025
To find out more
Get more information from the trial website below.
REPAIR-MDS Trial Website
The REPAIR-MDS trial website which has regularly updated information about who to contact, trial eligibility criteria, trial sites and more.
- Read more at the REPAIR-MDS trial website
- For more detail, read the section on Information for Participants
REPAIR-MDS Central Management Team
Dr Stephen Jenkins is Lead (Clinical) Chief Investigator on the REPAIR-MDS trial and consultant haematologist at Russells Hall Hospital, Dudley.
Dr Manoj Raghavan is Deputy (Clinical) Chief Investigator on the REPAIR-MDS trial. He is a consultant haematologist based at the Centre for Clinical Haematology.
Professor Janet Dunn is Co-Chief Investigator & Professor of clinical trials & head of cancer trials at - Warwick Clinical Trials Unit.
Sophie Gasson is a PPI Research Fellow at Warwick Clinical Trials Unit.
A brief introduction to REPAIR-MDS from Co-Chief Investigator Dr Manoj Raghavan
